- Home
- CBIO vs OPFI Comparison
CBIO vs OPFI Comparison
Compare CBIO & OPFI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CBIO
- OPFI
- Stock Information
- Founded
- CBIO 2003
- OPFI 2009
- Country
- CBIO United States
- OPFI United States
- Employees
- CBIO N/A
- OPFI N/A
- Industry
- CBIO
- OPFI Finance: Consumer Services
- Sector
- CBIO
- OPFI Finance
- Exchange
- CBIO Nasdaq
- OPFI Nasdaq
- Market Cap
- CBIO 308.0M
- OPFI 300.3M
- IPO Year
- CBIO N/A
- OPFI N/A
- Fundamental
- Price
- CBIO $14.29
- OPFI $10.17
- Analyst Decision
- CBIO Strong Buy
- OPFI Buy
- Analyst Count
- CBIO 5
- OPFI 2
- Target Price
- CBIO $25.60
- OPFI $11.75
- AVG Volume (30 Days)
- CBIO 98.3K
- OPFI 1.3M
- Earning Date
- CBIO 07-31-2025
- OPFI 08-06-2025
- Dividend Yield
- CBIO N/A
- OPFI 9.79%
- EPS Growth
- CBIO N/A
- OPFI N/A
- EPS
- CBIO N/A
- OPFI N/A
- Revenue
- CBIO N/A
- OPFI $320,831,000.00
- Revenue This Year
- CBIO N/A
- OPFI $116.69
- Revenue Next Year
- CBIO N/A
- OPFI $9.90
- P/E Ratio
- CBIO N/A
- OPFI N/A
- Revenue Growth
- CBIO N/A
- OPFI 31.26
- 52 Week Low
- CBIO $10.83
- OPFI $3.93
- 52 Week High
- CBIO $21.40
- OPFI $17.73
- Technical
- Relative Strength Index (RSI)
- CBIO 52.92
- OPFI 46.36
- Support Level
- CBIO $13.50
- OPFI $10.11
- Resistance Level
- CBIO $16.00
- OPFI $10.76
- Average True Range (ATR)
- CBIO 0.79
- OPFI 0.47
- MACD
- CBIO 0.16
- OPFI 0.08
- Stochastic Oscillator
- CBIO 39.68
- OPFI 51.49
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.
About OPFI OppFi Inc.
OppFi Inc is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to extend credit access to everyday Americans. It recognizes revenue through finance charges on installment and SalaryTap contracts based on the interest method.